Lee Financial Co Has $451,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Lee Financial Co grew its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 8.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,765 shares of the company’s stock after acquiring an additional 211 shares during the quarter. Lee Financial Co’s holdings in Johnson & Johnson were worth $451,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. Red Wave Investments LLC raised its holdings in Johnson & Johnson by 2.0% during the 2nd quarter. Red Wave Investments LLC now owns 2,986 shares of the company’s stock valued at $530,000 after acquiring an additional 59 shares during the period. Argus Investors Counsel Inc. grew its position in shares of Johnson & Johnson by 0.6% in the second quarter. Argus Investors Counsel Inc. now owns 10,936 shares of the company’s stock valued at $1,941,000 after purchasing an additional 61 shares in the last quarter. Alta Capital Management LLC raised its stake in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Alta Capital Management LLC now owns 15,824 shares of the company’s stock valued at $2,808,000 after purchasing an additional 61 shares during the period. Paces Ferry Wealth Advisors LLC grew its holdings in Johnson & Johnson by 0.7% during the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock valued at $1,425,000 after buying an additional 62 shares in the last quarter. Finally, Mason & Associates Inc increased its position in shares of Johnson & Johnson by 4.9% during the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after buying an additional 62 shares during the period. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In other news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction that occurred on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now owns 40,133 shares in the company, valued at $6,869,966.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Johnson & Johnson news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the sale, the vice president now owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares of the company’s stock, valued at $2,707,775. The disclosure for this sale can be found here. Insiders sold 233,611 shares of company stock worth $40,960,735 in the last ninety days. 0.35% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on JNJ shares. Barclays initiated coverage on shares of Johnson & Johnson in a research note on Monday, October 17th. They set an “equal weight” rating and a $175.00 price objective for the company. Citigroup raised their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a report on Monday, December 12th. Sanford C. Bernstein cut their price objective on Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Raymond James lowered their target price on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 19th. Finally, Bank of America decreased their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Seven research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $181.75.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $168.31 on Tuesday. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The stock has a market cap of $440.04 billion, a PE ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56. The company’s fifty day moving average is $176.07 and its 200 day moving average is $171.13. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.